Literature DB >> 24395126

Increased platelet binding to circulating monocytes in idiopathic pulmonary fibrosis.

Ahmed Fahim1, Michael G Crooks, Alyn H Morice, Simon P Hart.   

Abstract

PURPOSE: Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonia and its prognosis is poor. Epidemiological evidence suggests an association of IPF with vascular disease and thrombotic tendency, which may be related to platelet activation.
METHODS: Platelet-monocyte adhesion in peripheral blood was examined by flow cytometry in patients with IPF (n = 19), interstitial lung disease (ILD) other than IPF (n = 9), and control subjects without pulmonary fibrosis (n = 14). Expression of platelet activation markers P-selectin (CD62P), PSGL-1 (CD162), and CD40 ligand (CD40L) on leukocytes and platelets were studied. Plasma concentrations of soluble P-selectin and CD40L were measured by ELISA.
RESULTS: Significantly elevated levels of platelet-monocyte binding were found in patients with IPF (35.6 ± 4.34 % [mean ± SEM]) compared with patients with non-IPF ILD (23.5 ± 3.68 %) and non-ILD control subjects (16.5 ± 2.26 %; P < 0.01). There was a trend towards increased divalent cation-independent platelet-monocyte binding in IPF (6.0 ± 0.77 % [mean ± SEM]) compared with non-IPF ILD (4.3 ± 1.38 %) and control subjects without ILD (3.1 ± 1.75 %; P = 0.058). There was no differential surface expression of platelet activation markers on subsets of leukocytes or platelets. Plasma concentrations of CD40L and soluble P-selectin did not differ between IPF and control subjects. Platelet-monocyte binding had no significant correlation with percent predicted TLco or FVC.
CONCLUSIONS: Platelet-monocyte binding is increased in IPF, suggesting increased platelet activation. This conjugation is predominantly calcium-dependent, but there may be more calcium-independent adhesion in IPF. These findings support further research into the role of platelet activation in IPF.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24395126     DOI: 10.1007/s00408-013-9546-5

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  41 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

Review 2.  Regulation of PDGF and its receptors in fibrotic diseases.

Authors:  James C Bonner
Journal:  Cytokine Growth Factor Rev       Date:  2004-08       Impact factor: 7.638

3.  Heterogeneous remodeling of lung vessels in idiopathic pulmonary fibrosis.

Authors:  Edwin Roger Parra; Yonara Rivelle David; Lígia Rodrigues Silvério da Costa; Alexandre Ab'Saber; Rogerio Sousa; Ronaldo Adib Kairalla; Carlos Roberto Ribeiro de Carvalho; Mario Terra Filho; Vera Luiza Capelozzi
Journal:  Lung       Date:  2005 Jul-Aug       Impact factor: 2.584

4.  Choice of anticoagulant critically affects measurement of circulating platelet-leukocyte complexes.

Authors:  Stylianos Bournazos; Jillian Rennie; Simon P Hart; Ian Dransfield
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-01       Impact factor: 8.311

Review 5.  Molecular targets in pulmonary fibrosis: the myofibroblast in focus.

Authors:  Chris J Scotton; Rachel C Chambers
Journal:  Chest       Date:  2007-10       Impact factor: 9.410

6.  The CD40 ligand expressed by human B cells costimulates B cell responses.

Authors:  A C Grammer; M C Bergman; Y Miura; K Fujita; L S Davis; P E Lipsky
Journal:  J Immunol       Date:  1995-05-15       Impact factor: 5.422

7.  Factor V leiden homozygosity, dyspnea, and reduced pulmonary function.

Authors:  Klaus Juul; Anne Tybjaerg-Hansen; Jann Mortensen; Peter Lange; Jørgen Vestbo; Børge G Nordestgaard
Journal:  Arch Intern Med       Date:  2005-09-26

8.  The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis.

Authors:  Cynthia M Magro; James Allen; Amy Pope-Harman; W James Waldman; Patrick Moh; Susan Rothrauff; Patrick Ross
Journal:  Am J Clin Pathol       Date:  2003-04       Impact factor: 2.493

9.  Circulating activated platelets assist THP-1 monocytoid/endothelial cell interaction under shear stress.

Authors:  G Theilmeier; T Lenaerts; C Remacle; D Collen; J Vermylen; M F Hoylaerts
Journal:  Blood       Date:  1999-10-15       Impact factor: 22.113

10.  Platelet-monocyte complexes support monocyte adhesion to endothelium by enhancing secondary tethering and cluster formation.

Authors:  P da Costa Martins; N van den Berk; Laurien H Ulfman; L Koenderman; P L Hordijk; J J Zwaginga
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-11-13       Impact factor: 8.311

View more
  5 in total

1.  Platelet polyphosphate induces fibroblast chemotaxis and myofibroblast differentiation.

Authors:  Patrick M Suess; Stephanie A Smith; James H Morrissey
Journal:  J Thromb Haemost       Date:  2020-09-10       Impact factor: 5.824

2.  Extracellular Vesicle Surface Signatures in IPF Patients: A Multiplex Bead-Based Flow Cytometry Approach.

Authors:  Miriana d'Alessandro; Piera Soccio; Laura Bergantini; Paolo Cameli; Giulia Scioscia; Maria Pia Foschino Barbaro; Donato Lacedonia; Elena Bargagli
Journal:  Cells       Date:  2021-04-28       Impact factor: 6.600

3.  Inhaled beclomethasone/formoterol in idiopathic pulmonary fibrosis: a randomised controlled exploratory study.

Authors:  Caroline E Wright; Simon D Fraser; Kayleigh Brindle; Alyn H Morice; Simon P Hart; Michael G Crooks
Journal:  ERJ Open Res       Date:  2017-12-14

Review 4.  Platelet-Monocyte Aggregates: Understanding Mechanisms and Functions in Sepsis.

Authors:  Guang Fu; Meihong Deng; Matthew D Neal; Timothy R Billiar; Melanie J Scott
Journal:  Shock       Date:  2021-02-01       Impact factor: 3.533

Review 5.  Endothelial cells, neutrophils and platelets: getting to the bottom of an inflammatory triangle.

Authors:  Tima Dehghani; Alyssa Panitch
Journal:  Open Biol       Date:  2020-10-14       Impact factor: 6.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.